Oronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004, 43:1663?669. Anand DV, Lim E, Hopkins D, Corder R, Ahaw LJ, Sharp P, Lipkin D, Lahiri A: Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 2006, 27:713?21.doi:10
Oronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004, 43:1663?669. Anand DV, Lim E, Hopkins D, Corder R, Ahaw LJ, Sharp P, Lipkin D, Lahiri A: Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 2006, 27:713?21.doi:10
Ociety of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2012, 33(13):1635?701. Elkeles R, Godsland I, Feher M, Rubens MB, Roughton M, Nugara F, Humphries SE, Richmond W, Flather MD: Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J 2008, 29:2
Predictor models. Finally, comparisons of areas under ROC curves (AUC) were performed between predictor models and cardiovascular events predictors using MedCalc for Windows version 9.2.0.1.ResultsStudy population and CT resultsEighty-five patients were referred for CT. Demographic, clinical and laboratorial characteristics of study populationTable 4 Risk factors and risk profile by the time of CT
Predictor models. Finally, comparisons of areas under ROC curves (AUC) were performed between predictor models and cardiovascular events predictors using MedCalc for Windows version 9.2.0.1.ResultsStudy population and CT resultsEighty-five patients were referred for CT. Demographic, clinical and laboratorial characteristics of study populationTable 4 Risk factors and risk profile by the time of CT
Cific 1 (EC 2.7.1.30) R.WLLDNVR.K Glycine dehydrogenase [decarboxylating], mitochondrial P.RVNPLKMSPHSL.T Glycogen [starch] synthase, muscle (EC 2.4.1.11) T.KAKVTGDEWGDNYF.L Glycogen phosphorylase, brain form (EC 2.4.1.1) F.YELEPEKFQ.N D.LQIPPPNIPR.DP06737 Q96J90 Q8NFP4 O60551 P41250 Q14789 Q14789 Q08378 Q96S52 Q14444 Q96S75 Q9H2Q8 O60383 Q9C056 Q9UL65 O15068 P50151 Q14663 P00737 P00737 1 1 1 2 3
Cific 1 (EC 2.7.1.30) R.WLLDNVR.K Glycine dehydrogenase [decarboxylating], mitochondrial P.RVNPLKMSPHSL.T Glycogen [starch] synthase, muscle (EC 2.4.1.11) T.KAKVTGDEWGDNYF.L Glycogen phosphorylase, brain form (EC 2.4.1.1) F.YELEPEKFQ.N D.LQIPPPNIPR.DP06737 Q96J90 Q8NFP4 O60551 P41250 Q14789 Q14789 Q08378 Q96S52 Q14444 Q96S75 Q9H2Q8 O60383 Q9C056 Q9UL65 O15068 P50151 Q14663 P00737 P00737 1 1 1 2 3
Diovascular events (CVEV) in T2DP. Methods: Eighty-five consecutive T2DP undergoing CT (Phillips Brilliance, 16-slice) with CS and CTA were prospectively enrolled in a transversal case-control study. Patients were followed for 48 months (range 18 - 68) to assess CVEV: cardiovascular death, acute coronary syndrome, revascularisation and stroke. Potential predictors of CVEV were identified. Predicti